从复杂的全球和 HTA 成本效果分析模型，到本地预算影响分析模型和用户友好型市场准入工具，我们经验丰富、尽职尽责、以客户为中心的团队着力于定制模型以满足您的需求，并确保在您的特定预算范围内交付
Our Health Economics team were commissioned to build a cost-effectiveness model of a screening programme for an infectious disease to support the value story of a client’s existing therapy.
Having initially built the model from a UK perspective, we subsequently performed adaptations to multiple other European countries through engagement with local Affiliates and agencies. When the European Affiliates expressed an interest in submitting conference abstracts and publishing the model, we were able to provide ongoing support and utilise our expertise in health economic publications to deliver these projects efficiently and to high quality. We provided leadership in project management and project team consistency throughout, liaising with varied stakeholders including the European client, local affiliates and leading clinicians in the field across project components.
In addition to several country adaptations, the model has been successfully presented at four relevant congresses and two peer-reviewed manuscripts are currently being prepared.
Costello Medical were approached to provide economic modelling support for two concurrent oncology HTA submissions for a highly novel therapy, as well as writing of the submissions themselves.
The team’s extensive prior experience in oncology HTA submissions meant we were able to provide strategic modelling input, advising on the incorporation of innovative modelling approaches appropriate to the available data and determining the most appropriate choices regarding model inputs and assumptions for the indications under consideration.
We subsequently implemented extensive adaptations to the existing global models based on decisions taken with the client, working across both indications simultaneously to ensure efficiency and consistency of delivery across the two submissions. Despite considerable time pressure on the project, our detailed planning and proactive communication within our team and with the client ensured that that extensive thorough and robust quality control checks retained their priority in the project plan. This was reflected in the lack of errors identified for either model following expert technical review as part of the HTA process.
Our health economic support played a vital contribution to ensuring the successful and timely delivery of the two HTA submissions to the same deadline. Our team has also been able to provide the client with ongoing support and valuable continuity by performing adaptations for subsequent HTA submissions in other jurisdictions.
As part of a large suite of projects, we were asked to develop a global cost-effectiveness model to inform a client’s Market Access and pricing strategy, as well as future HTA submissions.
Our Health Economists worked closely with colleagues who were delivering the corresponding Systematic Literature Reviews and Network Meta-Analysis as part of a multidisciplinary team to ensure the outputs from the literature reviews and statistical analyses were as relevant as possible to the required model inputs. Close collaboration resulted in efficient and timely delivery of all project components and ensured that the model was demonstrably founded on an appropriate and defensible evidence base.
Following development of the global model, we have provided ongoing technical support to client affiliates as this model has been adapted for HTA requirements in local markets. We are also continuing our long-term collaboration with the client to provide updates across all key project components, including the global economic model, as new data are released, in order to support their emerging needs in a competitive market.
To help inform the client’s strategy and responses to a review by the Institute for Clinical and Economic Review (ICER), Costello Medical were asked to adapt a UK cost-effectiveness model to the US setting.
Based on the inputs and assumptions reported in the ICER review, we were able to develop a model that could “shadow” the cost-effectiveness model used by ICER. By exploring changes to the modelling approach used in the ICER model, we were then able to help strategically guide the client when submitting comments to ICER regarding their preferred inputs and assumptions. Additionally, using our experience from the UK of health technology assessments in the same disease area, we were able to offer detailed insight into the cost-effectiveness analyses during internal client workshops to provide further support to the client during the ICER review.
Our client was able to respond to ICER with a clearer understanding of what the implications might be for the cost-effectiveness results. Results from the adapted model using the client’s preferred modelling approach were presented as a poster at the Academy of Managed Care and Pharmacy Annual Meeting 2017.